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SUMMARY
Objective: To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopa-
thy (IIE) with successful management.
Case Reports: The patient in the first case developed grade 4 toxicity and had a partial response after the
fourth dose of intravenous methylene blue was administered. Full recovery occurred 4 days after the develop-
ment of IIE. The patient in the second case, who had grade 3 toxicity, had completely recovered 32 hours after
the first dose of thiamine.
Conclusion: Careful evaluation of patients with recurrent gynecologic cancers and vigilance during infusion of
chemotherapeutic regimens are important in reducing the risk and timely management of IIE. Both methylene
blue and thiamine appear to be effective treatments for IIE. [Taiwan J Obstet Gynecol 2010;49(1):77–80]
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Introduction
Ifosfamide is an alkylating agent and isomer of cyclo-
phosphamide. Ifosfamide is used extensively in different
chemotherapeutic regimens to treat various malig-
nancies, such as gynecologic, testicular, head and neck
cancers, lymphomas, Ewing’s sarcoma, and osteogenic
sarcomas. Common adverse effects of ifosfamide in-
clude alopecia, nausea, vomiting, bone marrow sup-
pression, and hemorrhagic cystitis. However, a specific
side effect of ifosfamide is central nervous system toxi-
city, which occurs in 10–30% (mean, 12%) of patients
after intravenous infusion [1]. The clinical presentation
of ifosfamide-induced encephalopathy (IIE) toxicity
ranges from mild somnolence, agitation, confusion, hal-
lucinations, and deep coma, while the most common
presentation is confusion [2,3]. Here, we report two
patients with recurrent uterine sarcoma that developed
IIE shortly after administration of chemotherapeutic
regimens containing ifosfamide. The relevant clinical
issues regarding the development, risk factors, clinical
presentations, diagnosis, treatment, and prophylactic
measures and outcomes of IIE are also discussed.
Case Reports
Case 1
A 79-year-old woman with recurrent malignant mixed
müllerian tumor of the uterus was admitted for a third
cycle of chemotherapy consisting of carboplatin (area
under the curve, 4), and ifosfamide (5 g/m2). The
patient had been treated with cisplatin, with a cumu-
lative dose of more than 300 mg/m2. Her physical
examination revealed a bulky pelvic mass. The results of
laboratory data included the following: hemoglobin,
9.3 g/dL; sodium, 128 mmol/L; potassium, 2.1 mmol/
L; blood urea nitrogen, 31 mg/dL; serum creatinine,
2.3 mg/dL; and albumin 2.3 g/dL. Results of the
remaining examinations were normal. After electrolyte
supplementation and blood transfusion, she under-
went a third cycle of chemotherapy. Three hours after
*Correspondence to: Dr Mu-Hsien Yu, Department
of Obstetrics and Gynecology, Tri-Service General
Hospital, National Defense Medical Center, 325,
Section 2, Cheng-Kung Road, Neihu, Taipei 114,
Taiwan.
E-mail: h121976@yahoo.com.tw
Accepted: January 8, 2009
completion of ifosfamide given intravenously, she de-
veloped confusion, disorientation, and alternating inter-
vals of alertness and stupor. Approximately 6 hours
later, she became comatose and no longer opened her
eyes to painful stimuli. According to the National Can-
cer Institute common toxicity criteria, this patient dis-
played grade IV toxicity [1]. No peripheral neurologic
abnormalities were noted. Computed tomography of
the brain was normal. After careful exclusion of other
potential causes, a diagnosis of IIE was made. Treat-
ment with intravenous methylene blue (MB), 50 mg
every 4 hours, was initiated, and a total of six doses of
MB were administered. Partial improvement in symp-
toms was noted after four doses of MB, including
motor responses and opening of the eyes to painful
stimulation. She had a full recovery from the IIE 4 days
after the initiation of intravenous MB.
Case 2
A 56-year-old woman with recurrent endometrial stroma
sarcoma of the uterus was admitted for a second cycle of
chemotherapy using carboplatin (area under the curve,
5) and ifosfamide (5 g/m2). Bulky pelvic masses were
noted on physical examination. The results of laboratory
examination included a blood urea nitrogen of 46mg/dL,
serum creatinine of 2.0 mg/dL, and serum albumin of
3.4 mg/dL. Results of the remaining laboratory examina-
tions were normal. The patient had been previously
treated with cisplatin with a cumulative dose of more
than 480 mg/m2. Seventeen hours after completion of
intravenous infusion of ifosfamide, she developed pro-
longed daytime sleepiness, hallucinations, and severe
disorientation (grade III encephalopathy). The results
of cranial computed tomography and electroencepha-
lography were normal. Infectious, metabolic and or-
ganic causes were carefully excluded. She was treated
with 100 mg of thiamine given intravenously every 
4 hours. A marked improvement in the patient’s neu-
rologic symptoms was noted 16 hours after beginning
the thiamine treatment. She had full recovery 32 hours
after the first dose of thiamine.
Discussion
Ifosfamide has been widely used both as a single agent
and in combination therapy for a variety of soft tissue
and gynecologic cancers. In the registered Gynecologic
Oncology Group trials and reported cases, ifosfamide
has been used for previously treated or recurrent ovar-
ian epithelial tumors, squamous carcinoma of the
cervix, trophoblastic disease, and advanced or recur-
rent uterine sarcomas [4–7]. Ifosfamide is a prodrug
metabolized by cytochrome P450 to its active al-
kylating agents, 4-hydroxy-ifosfamide and ifosfamide
mustard. The selective dechloroethylation of ifos-
famide leads to the release of the neurotoxic molecule
chloroacetaldehyde. Other non-alkylating metabolites
are also formed and may be responsible for the toxicity
of the drug [2]. Cyclophosphamide does not exhibit
neurotoxicity.
The exact pathophysiologic mechanisms for devel-
opment of IIE have been related to the accumulation of
various degradation products such as chloroacetalde-
hyde. Chloroacetaldehyde can cross the blood–brain
barrier and is a potential neurotoxic substance [2].
Based on the findings of glutaric acid and sarcosine in
the urine of a patient with IIE, Kupfer et al [8] hypoth-
esized possible pathways by which ifosfamide metabo-
lites could induce neurotoxicity. These biochemical
abnormalities are similar to those of patients with glu-
taric aciduria type II, a disorder of mitochondrial fatty
acid oxidation [8]. Subsequent investigations revealed
that chloroethylamine may be another neurotoxic me-
tabolite of ifosfamide [2]. The metabolites of chloroethy-
lamine can inhibit the electron-binding flavoproteins
in the mitochondrial respiratory chain, which may also
lead to a disturbance of the intracellular nicotinamide
adenine dinucleotide–reduced nicotinamide adenine
dinucleotide balance, with the accumulation of nicoti-
namide adenine dinucleotide. This in turn prevents the
dehydrogenation of aldehydes, such as the ifosfamide
metabolite, chloroacetaldehyde, which requires nicoti-
namide adenine dinucleotide for oxidation.
IIE is not an uncommon side effect occurring in
10–30% (mean, 12%) of patients following intravenous
infusion of ifosfamide. However, grade 3 and grade 4
toxicity accounted for 16.2% of patients [9]. The re-
ported risk factors for the development of IIE were hy-
poalbuminemia, elevated serum creatinine level, hepatic
insufficiency, the presence of tumors in the lower ab-
domen and pelvis, poorer performance status prior to
treatment, previous or concomitant treatment with
cisplatin, prior central nervous system disease, and ad-
vanced age [1]. Greater incidence of neurotoxicity had
been observed in higher doses and shorter duration
intravenous administration, suggesting a relationship
with maximum plasma concentration. However, a ret-
rospective cohort study by David and Picus [3] re-
ported that the role of peak ifosfamide concentration,
increased serum creatinine, and bulky abdominal dis-
ease as risk factors for IIE are controversial, with the
dose-toxicity relationship, infusion rate, or infusion
duration of ifosfamide not being significantly different
between control subjects and patients who developed
encephalopathy.
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Impaired renal function may indicate a role for renal
metabolism and/or excretion of the various causative
agents of encephalopathy. Bulky pelvic tumors may be
associated with some degrees of obstructive nephro-
pathy, further deteriorating renal function. Previous
cumulative dosages of cisplatin may be related to the
decreased clearance of ifosfamide or its active meta-
bolites owing to cisplatin-induced renal tubular dam-
age [1]. In gynecologic cancers settings, impaired renal
function, bulky tumors in the pelvis, and pretreatment
with cisplatin and hypoalbuminemia are common po-
tential risk factors that warrant particular caution while
administering ifosfamide.
IIE is essentially a clinical diagnosis. Onset of en-
cephalopathy ranges from 12 to 146 hours after be-
ginning of infusion [10]. No electroencephalography
or radiographic changes specific to this condition have
been identified [3]. According to the National Cancer
Institute common toxicity criteria, IIE is classified into
four grades. Grade 1 is represented by dazed or slightly
depressive periods, grade 2 neurotoxicity is marked by
extensive sleep or agitation, grade 3 toxicity is deter-
mined by heavy depression, mild hallucinations or a
stuporous condition, and grade 4 encephalopathy is
diagnosed in patients with manifested state of halluci-
nations or coma.
The first use of MB for the treatment and prophy-
laxis of IIE was reported by Kupfer et al in 1994 [11].
Intravenous thiamine infusion in the management of
IIE has also been suggested [1]. MB exhibits several
synergistic modes of action, which overcome the dose-
limiting neurotoxicity induced by ifosfamide [8]. MB
may act as an alternative electron acceptor, replacing
the inhibited flavoproteins and thus restoring the mito-
chondrial respiratory chain [12]. MB may also oxidize
nicotinamide adenine dinucleotide, allowing dehydro-
genation of aldehydes [13]. IIE is treated with MB
50 mg (1% aqueous solution over 5 minutes), six times
daily [2]. The neurologic features of ifosfamide are
akin to Wernicke encephalopathy, which is caused by
severe thiamine deficiency often related to alcoholism.
Management of IIE with intravenous thiamine is usu-
ally given at 100 mg diluted in 100 mL of normal saline,
as a 10-minute infusion every 4 hours until resolution or
significant improvement of symptoms [1,14]. The side
effect of MB, at doses exceeding 4 mg/kg, may cause
hemolytic anemia, and blue-green discoloration of the
urine and feces [15]. The side effects of thiamine are
uncommon and include local irritation, itching, sweat-
ing, and nausea [14]. There is no evidence suggesting
that one is superior to the other.
Intravenous infusion of albumin is thought to act
by binding chloroacetaldehyde, thereby preventing it
from crossing the blood–brain barrier. Hemodialysis
can remove ifosfamide and its metabolites and has
been shown to reverse encephalopathy [16]. Glucose
infusion has also been shown to be another effective
option in the treatment of IIE [17]. Prophylactic meas-
ures can be applied in patients who are at high risk or
have had IIE during prior therapy. MB (50 mg) can be
given orally or intravenously 3–4 times a day, starting
the first dose on the day before the beginning of
chemotherapy. Thiamine (100 mg) can be given three
times a day during chemotherapy [18].
The neurotoxicity of ifosfamide is generally self-
limiting and reversible between 12 and 72 hours. How-
ever, encephalopathy can, in rare cases, result in patient
death [19]. In conclusion, ifosfamide is widely used 
in chemotherapeutic regimens in gynecologic cancers.
Gynecologic oncologists should be especially aware 
of the neuropsychiatric complications of ifosfamide
when treating progression or recurrence of uterine,
cervical or ovarian cancers. It is, therefore, important
to recognize patients at risk for IIE, to objectively 
monitor patient responses, and to determine appro-
priate management, such as discontinuation of ifos-
famide or prophylactic use and treatment with MB 
or thiamine.
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